Phathom Pharmaceuticals, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual filing; the filing does not provide a separate Q4 income statement. Phathom is a commercial-stage biopharmaceutical company developing and selling vonoprazan-based gastrointestinal treatments.
Business context and reporting period
FDA approvals in October and November 2023 cleared the way for U.S. commercial launches of VOQUEZNA for erosive GERD and H. pylori infection, and VOQUEZNA TRIPLE PAK and DUAL PAK for H. pylori infection. Sales began in November 2023. The company had generated only limited revenue by year-end and continues to rely on vonoprazan as its principal commercial and development asset.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Net product revenue | $0.7 million | None |
| Cost of revenue / gross profit | $0.2 million / $0.5 million | None |
| Research and development | $49.9 million | $71.4 million |
| Selling, general and administrative | $117.9 million | $101.0 million |
| Operating loss | $167.3 million | $172.4 million |
| Interest expense | $42.0 million | $27.3 million |
| Net loss | $201.6 million | $197.7 million |
| Basic and diluted net loss per share | $3.93 | $5.05 |
| Cash used in operating activities | $137.6 million | $146.5 million |
Year-end cash and cash equivalents were $381.4 million; total current assets were $397.4 million and current liabilities $38.8 million. Total assets were $413.8 million, total liabilities $486.6 million, and stockholders’ deficit $72.8 million. The reported $0.5 million gross profit is not a reliable indicator of future margins: some pre-approval manufacturing costs had already been expensed as R&D.
At December 31, 2023, Hercules term-loan debt had $148.1 million principal outstanding and a $137.8 million net carrying value. The revenue-interest financing liability had a $306.9 million carrying value, including a $7.1 million current portion. These financing arrangements contributed to higher interest expense. Operating cash outflow improved by $9.0 million year over year, while net loss increased by $3.9 million. Financing activities provided $367.6 million, including $172.7 million net revenue-interest financing proceeds, $155.6 million from stock issuances, and $39.3 million of net debt proceeds.
Material changes versus 2022
- Revenue began in 2023, totaling $0.7 million after the November launch; no product revenue was reported in 2022.
- R&D expense declined $21.5 million, primarily from lower clinical-trial and manufacturing costs; SG&A rose $16.9 million, largely reflecting higher personnel costs as Phathom built its commercial organization.
- Interest expense increased $14.7 million, reflecting the financing structure and accretion of the revenue-interest liability. Net loss increased despite a lower operating loss.
- Cash and cash equivalents rose from $155.4 million to $381.4 million, primarily due to financing proceeds, including a $141.4 million net public offering and revenue-interest financing.
Outlook, commentary and risks
- Management estimates current cash, the remaining $160 million potentially available under the Hercules facility, and anticipated product revenue will fund operations through the end of 2026. This forecast depends on assumptions, including future sales and access to loan tranches; management states there is no substantial doubt about continuing as a going concern for at least 12 months.
- The FDA assigned July 19, 2024 as the target action date for the Non-Erosive GERD daily-treatment NDA. If approved, Phathom anticipated a U.S. launch in Q3 2024. It also planned a Phase 3 trial of as-needed dosing and a Phase 2 EoE trial later in 2024.
- Phathom reported approximately 60 million commercially covered U.S. lives for VOQUEZNA tablets as of February 2024, about 38% of estimated commercial lives. Coverage, reimbursement, pricing, physician adoption and competition from generic PPIs remain important commercialization uncertainties.
- In February 2023, the FDA issued complete response letters concerning the erosive GERD NDA and supplements for the H. pylori products, requesting stability data showing the nitrosamine impurity N-nitroso-vonoprazan would remain at or below the FDA’s 96 ng/day acceptable intake throughout shelf life. The relevant supplements and NDA were approved in October and November 2023, respectively.
- The Hercules loan matures in December 2027, bears variable cash interest currently subject to a 9.85% floor and 10.35% cap, and is secured by substantially all assets. Financial performance and minimum-cash covenants begin in September 2024. The revenue-interest agreement provides investors a 10% royalty on vonoprazan product net sales, subject to step-downs and a 200%-of-investment payment cap, alongside minimum-return provisions.
- Supply depends on third parties, including Catalent, Evonik and Sandoz. The company also disclosed that the February 2024 Change Healthcare cyber incident disrupted its copay assistance transactions and some pharmacies’ ability to fill prescriptions; the duration and extent were not clear in the filing.
- Other material risks include sustained operating losses, potential need for further capital, uncertain launch execution, regulatory and product-safety risks, patent and exclusivity uncertainty, and concentrated wholesale-distributor exposure. Three customers represented 86% of 2023 product sales and 87% of year-end accounts receivable.
Most important facts for investors to verify
- Subsequent quarterly sales, prescriptions, net pricing, gross-to-net adjustments, inventory levels and product gross margins as commercialization scales.
- Whether the July 19, 2024 FDA action occurred as expected, and the status and timing of the planned clinical programs.
- Actual cash burn, financing availability and Hercules covenant compliance, especially after the September 2024 covenant start date.
- The revenue-interest agreement’s effective cost, future royalty burden and minimum-return exposure relative to actual product sales.
- Progress in expanding payer access and resolving the disclosed Change Healthcare disruption, along with any continuing supply or customer-concentration issues.
- The scope and duration of vonoprazan’s NCE exclusivity: the company says the additional five-year QIDP extension should apply to VOQUEZNA, but notes that the FDA had not updated the Orange Book listing to reflect that extension.
The financial statements received an unqualified audit opinion. Management reported effective disclosure controls and internal control over financial reporting; the filing did not include an auditor attestation on internal controls under the emerging-growth-company exemption.